CLOs on the Move

Esschem

www.esschem.com

 
Esschem is the worlds most respected manufacturer of specialty acrylic polymers and monomers for medical and cosmetic uses.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.esschem.com
  • 4000, Columbia Ave
    Marcus Hook, PA USA 19061
  • Phone: 800.765.9637

Executives

Name Title Contact Details

Similar Companies

MacroCap Labs

MacroCap Labs is a contract manufacturing company founded in 2010. With steady improvements in quality and capacity, we have become one of the top contract manufacturers in the state of Florida. Our FDA registered facility ensures that we meet or excee...

SemBioSys Genetics

SemBioSys Genetics is a Calgary, AB-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Exela Pharma Sciences

Exela Pharma Sciences is a Lenoir, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Next Generation Clinical Research Consulting

Next Generation Clinical Research Consulting is a Oregon, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Zentaris

Aeterna Zentaris Inc. is a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The Company`s lead product, Macrilen™ (macimorelin), is the first and only U.S. FDA and European Commission approved oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). Macrilen™ is currently marketed in the United States through a license agreement with Novo Nordisk and Aeterna Zentaris receives double-digit royalties on sales. Aeterna Zentaris owns all rights to macimorelin outside of the U.S. and Canada. Aeterna Zentaris is also leveraging the clinical success and compelling safety profile of macimorelin to develop it for the diagnosis of child-onset growth hormone deficiency (CGHD), an area of significant unmet need. The Company is actively pursuing business development opportunities for the commercialization of macimorelin in Europe and the rest of the world, in addition to other non-strategic assets to monetize their value.